The use of health economics to guide drug development decisions:Determining optimal values for an RSV-vaccine in a model-based scenario-analytic approach
Health-economic modelling is useful for assessing the clinical requirements and impact of new vaccines. In this study, we estimate the impact of potential vaccination for respiratory syncytial virus (RSV) of infants in the Netherlands. A decision analysis model was employed using seasonal data from a cohort of children (1996-1997 through 1999-2000) to assess hospitalisation, costs and impact of vaccination. Yearly, an estimated 3670 infants are hospitalised with RSV-infection in the Netherlands, vaccination protecting infants from 3 months of life onwards could prevent approximately 1000-3000... Mehr ...
| Verfasser: | |
|---|---|
| Dokumenttyp: | Artikel |
| Erscheinungsdatum: | 2007 |
| Reihe/Periodikum: | Bos , J M , Rietveld , E , Moll , HA , Steyerberg , E W , Luytjes , W , Wilschut , J C , de Groot , R & Postma , M J 2007 , ' The use of health economics to guide drug development decisions : Determining optimal values for an RSV-vaccine in a model-based scenario-analytic approach ' , Vaccine , vol. 25 , no. 39-40 , pp. 6922-6929 . https://doi.org/10.1016/j.vaccine.2007.07.006 |
| Schlagwörter: | health economics / RSV / vaccination / RESPIRATORY SYNCYTIAL VIRUS / YOUNG-CHILDREN / INFECTION / INFLUENZA / ILLNESS / IMPACT / HOSPITALIZATION / BRONCHIOLITIS / NETHERLANDS / MORTALITY |
| Sprache: | Englisch |
| Permalink: | https://search.fid-benelux.de/Record/base-29191483 |
| Datenquelle: | BASE; Originalkatalog |
| Powered By: | BASE |
| Link(s) : | https://hdl.handle.net/11370/7afe72f8-646d-4b5c-a7a8-8d41bcda1c36 |
